https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/NRG-Therapeutics-spotlight-film.jpg400600Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-03-27 08:00:502026-08-14 11:19:05NRG Therapeutics CEO Spotlight Video SBC
https://www.nrgtherapeutics.com/wp-content/uploads/2026/02/ScripAsks_NRG.jpg394596Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-02-06 08:00:372026-08-14 14:55:55Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/BusinessWeekly_NRG.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-01-28 08:00:162026-08-14 11:19:20Founder-CEO Interview Series
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Shutterstock_657435445-1200x800-c-default.jpg8001200Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-01-26 08:01:292026-08-14 13:36:48Disease-modifying treatment for ALS enters Phase I
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Target-ALS.webp8001200Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-01-26 08:00:022026-08-14 11:36:51Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Mitochondria-1.webp350700Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-01-16 08:00:242026-08-14 12:44:40Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial – Target ALS
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/3D-Brain.jpg8001200Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2026-01-09 08:00:502026-08-14 12:48:43NRG doses first volunteers in mitochondrial ALS trial
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/DDW-new-advisor-from-MJFF-banner.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-12-02 08:01:172026-08-14 13:36:04Michael J Fox Foundation adviser joins NRG Therapeutics
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/thepharmaletter-banner.webp8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-12-02 08:00:352026-08-14 12:54:04NRG Therapeutics expands team with CDO appointment
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/DDW-new-appointment-banner.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-12-01 08:00:342026-08-14 12:55:39NRG Therapeutics appoints Paul Thompson as CDO
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/pwc-banner.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-11-30 08:00:592026-09-09 17:39:23UK Life Sciences Future50 – Momentum in an evolving landscape
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/labiotech-25Nov25-banner.jpg8441500Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2025-11-25 08:00:512026-08-14 12:58:4011 neuroscience biotech companies you should know about
NRG Therapeutics CEO Spotlight Video SBC
SBC
Watch now
Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
SCRIP
Read more
Founder-CEO Interview Series
Sejelas
Read more
Disease-modifying treatment for ALS enters Phase I
Drug Discovery World
Read more
Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial
Target ALS
Read more
Target ALS Grantee NRG Therapeutics Advances NRG5051 into Phase I Clinical Trial – Target ALS
ALS News Today
Read more
NRG doses first volunteers in mitochondrial ALS trial
Longevity Technology
Read more
Michael J Fox Foundation adviser joins NRG Therapeutics
Business Weekly
Read more
NRG Therapeutics expands team with CDO appointment
thepharmaletter
Read more
NRG Therapeutics appoints Paul Thompson as CDO
Drug Discovery World
Read more
UK Life Sciences Future50 – Momentum in an evolving landscape
pwc
Read more
(pdf)
11 neuroscience biotech companies you should know about
Labiotech
Read more